H04.152 Secondary lacrimal gland atrophy, left lacrimal gland

Name of the Condition

• Secondary Lacrimal Gland Atrophy, Left Lacrimal Gland (ICD-10 code: H04.152)

Summary

Secondary lacrimal gland atrophy, left lacrimal gland, refers to the degeneration or shrinkage of the left lacrimal gland due to an underlying condition or external factor, rather than a primary disorder of the gland itself. This condition can reduce tear production, leading to dry eye symptoms or other ocular complications. The lacrimal gland is critical for maintaining ocular surface health, and its atrophy may impact tear quality or quantity.

Causes

Causes include systemic diseases, chronic inflammation, or external factors that affect gland function. Examples are autoimmune disorders (e.g., Sjögren's syndrome), infections, radiation exposure, or trauma to the gland. Certain medications or surgical interventions near the gland may also contribute to secondary atrophy.

Risk Factors

Risk factors depend on the underlying cause but may include a history of autoimmune disease, prior radiation therapy to the head or eye area, chronic inflammatory conditions, or prolonged use of medications that suppress gland function. Age-related changes or genetic predisposition to gland degeneration may also play a role.

Symptoms

Symptoms can include persistent dry eye, eye irritation, redness, or a sensation of grittiness. Reduced tear production may lead to discomfort, blurred vision, or increased sensitivity to light. Some individuals may experience foreign body sensation or difficulty with eye closure.

Diagnosis

Diagnosis involves a thorough clinical evaluation, including a detailed patient history and physical examination of the eye. Diagnostic tests may include Schirmer’s test to measure tear production, slit-lamp examination to assess gland structure, and imaging studies (e.g., MRI or CT) to evaluate gland size or detect underlying causes. Blood tests or biopsies may be performed if an autoimmune or systemic condition is suspected.

Treatment Options

Treatment focuses on addressing the underlying cause and managing symptoms. Artificial tears or lubricating eye drops can alleviate dryness. In cases of inflammation, anti-inflammatory medications (e.g., corticosteroids) may be prescribed. If an autoimmune disorder is identified, systemic therapies targeting the underlying condition may be necessary. Surgical interventions are rarely required unless structural abnormalities are present.

Prognosis and Follow-Up

Prognosis depends on the underlying cause and the effectiveness of treatment. Early intervention can help manage symptoms and prevent complications. Regular follow-up with an ophthalmologist is recommended to monitor tear production, gland function, and ocular health. Adjustments to treatment plans may be needed based on symptom progression or response to therapy.

Complications

Complications may include chronic dry eye, corneal damage, or increased risk of eye infections due to reduced tear production. Severe atrophy can lead to persistent discomfort or vision impairment. If left untreated, secondary issues like blepharitis or conjunctivitis may develop.

Lifestyle & Prevention

Lifestyle modifications can help manage symptoms. Avoiding environmental irritants (e.g., smoke, wind) and using humidifiers may reduce dryness. Protecting the eyes with sunglasses and practicing good eyelid hygiene can minimize irritation. Staying hydrated and avoiding medications that exacerbate dry eye (when possible) may also be beneficial.

When to Seek Professional Help

Seek medical attention if dry eye symptoms worsen, vision changes occur, or eye pain develops. Prompt evaluation is important if there is sudden onset of redness, swelling, or discharge, as these may indicate infection or other serious conditions. Regular check-ups are advised for individuals with known risk factors or underlying conditions affecting the lacrimal gland.

Tips for Medical Coders

When coding H04.152, ensure the left lacrimal gland is clearly documented. Verify that the atrophy is secondary (not primary) and linked to an underlying cause. Documentation should specify the affected gland and any associated conditions (e.g., autoimmune disease, radiation history) to support code assignment. Avoid coding for primary lacrimal gland disorders, as H04.152 is specific to secondary atrophy of the left gland.